Identification

Name
Phenylephrine
Accession Number
DB00388  (APRD00365)
Type
Small Molecule
Groups
Approved
Description

Phenylephrine is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

Structure
Thumb
Synonyms
  • (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
  • (-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
  • Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-
  • Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-
  • Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-
  • Fenilefrina
  • l-(3-Hydroxyphenyl)-N-methylethanolamine
  • Phenylephrine
  • Phenylephrinum
  • R(-)-Phenylephrine
External IDs
J8.601K
Product Ingredients
IngredientUNIICASInChI Key
Phenylephrine bitartrate27O3Q5ML5717162-39-9NHKOTKKHHYKARN-NDAAPVSOSA-N
Phenylephrine hydrochloride04JA59TNSJ61-76-7OCYSGIYOVXAGKQ-FVGYRXGTSA-N
Phenylephrine tannateDU5ATO7HYP1416-03-1Not applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minims Phenylephrine Hydrochloride 10%Solution / drops10 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Neo-SynephrineSolution1 %Intramuscular; Intravenous; SubcutaneousPfizer2002-11-01Not applicableCanada
Neo-synephrine Inj Liq 10mg/mlLiquid10 mgIntramuscular; Intravenous; SubcutaneousSterling Winthrop Inc.1992-12-311996-09-10Canada
Neo-synephrine Liq 1%Liquid1 %Intramuscular; Intravenous; SubcutaneousSanofi1996-09-142001-08-10Canada
Phenylephrine HydrochlorideSolution / drops2.5 mg/mLOphthalmicParagon Bio Teck, Inc.2013-04-15Not applicableUs
Phenylephrine HydrochlorideSolution / drops25 mg/mLOphthalmicAkorn2015-01-15Not applicableUs
Phenylephrine HydrochlorideInjection10 mg/mLIntravenousGeneral Injectables & Vaccines2013-04-02Not applicableUs
Phenylephrine HydrochlorideInjection10 mg/mLIntravenousCardinal Health2012-12-18Not applicableUs
Phenylephrine HydrochlorideInjection10 mg/mLIntravenousWest Ward Pharmaceutical2012-12-18Not applicableUs
Phenylephrine HydrochlorideInjection10 mg/mLIntravenousRemedy Repack2018-03-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Way Fast ActingSpray10 mg/mLNasalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2010-01-01Not applicableUs
7 Select Nasal Decongestant PETablet, film coated10 mg/1Oral7 Eleven2016-10-07Not applicableUs
Benylin Cold StripsStrip10 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson IncNot applicableNot applicableCanada
Benylin D for InfantsSolution1.25 mgOralPfizer Canada Inc., Consumer Healthcare Division2007-09-142007-11-05Canada
Berkley and Jensen Nasal Decongestant PE Non-Drowsy Maximum StrengthTablet10 mg/1OralBJWC2009-06-052017-11-22Us
Care One Nasal Decongestant PE Maximum Strength Non DrowsyTablet, film coated10 mg/1OralAmerican Sales Company2005-05-17Not applicableUs
Care One Nasal FourSpray1 g/100mLNasalAmerican Sales Company2004-05-24Not applicableUs
Care One Nose DropsLiquid1 mL/100mLNasalAmerican Sales Company2004-06-01Not applicableUs
CareOne Cold and SinusSolution / drops1 g/100mLNasalAmerican Sales Company2016-10-20Not applicableUs
CareOne Fast Acting NasalSpray1 g/100mLNasalAmerican Sales Company2016-11-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Cold and Allergy ChildrensPhenylephrine hydrochloride (2.5 mg/5mL) + Brompheniramine maleate (1 mg/5mL)LiquidOral7 Eleven2014-08-052017-11-22Us
7 Select Day Time ReliefPhenylephrine hydrochloride (5 mg/15mL) + Acetaminophen (325 mg/15mL) + Dextromethorphan hydrobromide (10 mg/15mL)SolutionOral7 Eleven2014-08-05Not applicableUs
7 Select Day Time ReliefPhenylephrine hydrochloride (5 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1)Capsule, liquid filledOral7 Eleven2014-04-22Not applicableUs
7 Select Hemorrhoidal Original StrengthPhenylephrine hydrochloride (2.5 mg/g) + Mineral oil (140 mg/g) + Petrolatum (749 mg/g)OintmentTopical7 Eleven2016-12-07Not applicableUs
7 Select Night Time Severe Cold Cough and FluPhenylephrine hydrochloride (10 mg/1) + Acetaminophen (650 mg/1) + Diphenhydramine hydrochloride (25 mg/1)Powder, for solutionOral7 Eleven2016-01-25Not applicableUs
7 Select Night Time severe cold, cough and fluPhenylephrine hydrochloride (10 mg/1) + Acetaminophen (650 mg/1) + Diphenhydramine hydrochloride (25 mg/1)Powder, for solutionOral7 Eleven2015-11-122018-03-29Us
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClPhenylephrine hydrochloride (5 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Doxylamine succinate (6.25 mg/1)Capsule, liquid filledOralCvs Pharmacy,inc2017-07-07Not applicableUs
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClPhenylephrine hydrochloride (5 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Doxylamine succinate (6.25 mg/1)Capsule, liquid filledOralCVS Health2017-11-30Not applicableUs
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and PHENYLEPHRINE HYDROCHLORIDEPhenylephrine hydrochloride (5 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1)Capsule, liquid filledOralJ.P. BUSINESS ENTERPRISE2014-12-01Not applicableUs
Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine HydrochloridePhenylephrine hydrochloride (5 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Doxylamine succinate (6.25 mg/1)Capsule, liquid filledOralGranules India Limited2017-07-07Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AiracofPhenylephrine hydrochloride (7.5 mg/5mL) + Codeine phosphate (7.5 mg/5mL) + Diphenhydramine hydrochloride (12.5 mg/5mL)LiquidOralCenturion Labs2010-01-082016-10-13Us
Anu-MedPhenylephrine hydrochloride (5 mg/1) + Fat, hard (1.77 g/1)SuppositoryRectalMajor1996-04-01Not applicableUs
CarbatussPhenylephrine hydrochloride (10 mg/5mL) + Guaifenesin (100 mg/5mL) + Pentoxyverine citrate (20 mg/5mL)LiquidOralGm Pharmaceuticals2000-11-012017-08-11Us
Centussin DhcPhenylephrine hydrochloride (7.5 mg/5mL) + Brompheniramine maleate (4 mg/5mL) + Dihydrocodeine bitartrate (3 mg/5mL)LiquidOralCenturion Labs2009-11-242016-10-13Us
Neo-SynephrinePhenylephrine hydrochloride (10 mg/mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines2010-08-012017-06-21Us
Phenylephrine HClPhenylephrine hydrochloride (50 ug/mL)Injection, solutionIntravenousCantrell Drug Company2012-10-162017-12-22Us
Phenylephrine HClPhenylephrine hydrochloride (40 ug/mL)Injection, solutionIntravenousCantrell Drug Company2012-06-15Not applicableUs
Phenylephrine HClPhenylephrine hydrochloride (1 mg/mL)Injection, solutionIntravenousCantrell Drug Company2013-03-142017-12-22Us
Phenylephrine HClPhenylephrine hydrochloride (160 ug/mL)Injection, solutionIntravenousCantrell Drug Company2011-06-30Not applicableUs
Phenylephrine HClPhenylephrine hydrochloride (300 ug/mL)Injection, solutionIntravenousCantrell Drug Company2013-10-25Not applicableUs
International/Other Brands
AK-Dilate / AK-Nefrin / Alconefrin / Dionephrine / Mesatone / Minims Phenylephrine / Mydfrin (Alcon Laboratories, Inc.) / Neo-Synephrine (Bayer) / Neofrin / Ocugestrin / Phenoptic / Prefrin / Rhinall / Spersaphrine / Visadron
Categories
UNII
1WS297W6MV
CAS number
59-42-7
Weight
Average: 167.205
Monoisotopic: 167.094628665
Chemical Formula
C9H13NO2
InChI Key
SONNWYBIRXJNDC-VIFPVBQESA-N
InChI
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
IUPAC Name
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
SMILES
CNC[[email protected]](O)C1=CC(O)=CC=C1

Pharmacology

Indication

Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

Structured Indications
Pharmacodynamics

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities.

Mechanism of action

In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities.

TargetActionsOrganism
AAlpha-1A adrenergic receptorNot AvailableHuman
AAlpha-1B adrenergic receptorNot AvailableHuman
AAlpha-1D adrenergic receptorNot AvailableHuman
Absorption

Completely absorbed after oral administration. It has a reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism in the intestinal wall. Compared to IV administration, bioavailability is approximately 38%. Peak serum concentrations are achieved approximately 0.75-2 hours following oral administration. Phenylephrine should be administered parenterally to achieve cardiovascular effects. Occasionally, systemic effects are observed following oral inhalation.

Volume of distribution
Not Available
Protein binding

95% binding-plasma proteins

Metabolism

Undergoes extensive first-pass metabolism in the intestinal wall and extensive metabolism in the liver. Sulfate conjugation, primarily in the intestinal wall, and oxidative metabolism by monoamine oxidase (MAO) represent the principle routes of metabolism. Glucuronidation occurs to a lesser extent. Phenylephrine and its metabolites are mainly excreted in urine/ .

Route of elimination
Not Available
Half life

2.1 to 3.4 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Phenylephrine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Phenylephrine.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Phenylephrine can be increased when it is combined with Acetaminophen.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Phenylephrine.Approved, Investigational
AmineptineAmineptine may increase the vasopressor activities of Phenylephrine.Illicit, Withdrawn
AmitriptylineAmitriptyline may increase the vasopressor activities of Phenylephrine.Approved
AmoxapineAmoxapine may increase the vasopressor activities of Phenylephrine.Approved
AmphetamineAmphetamine may increase the hypertensive activities of Phenylephrine.Approved, Illicit, Investigational
AtomoxetineAtomoxetine may increase the hypertensive activities of Phenylephrine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Phenylephrine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Benzphetamine.Approved, Illicit
Benzylpenicilloyl PolylysinePhenylephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Phenylephrine.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Phenylephrine.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Phenylephrine.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Phenylephrine.Investigational
CabergolineCabergoline may increase the hypertensive activities of Phenylephrine.Approved
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Phenylephrine.Approved, Withdrawn
CaroxazoneCaroxazone may increase the hypertensive activities of Phenylephrine.Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Phenylephrine.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Celiprolol.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Chlorphentermine.Illicit, Withdrawn
ClenbuterolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the vasopressor activities of Phenylephrine.Approved, Investigational, Vet Approved
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Phenylephrine.Approved
DesipramineDesipramine may increase the vasopressor activities of Phenylephrine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Phenylephrine.Approved, Investigational
DibenzepinDibenzepin may increase the vasopressor activities of Phenylephrine.Experimental
DihydroergocornineDihydroergocornine may increase the hypertensive activities of Phenylephrine.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive activities of Phenylephrine.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive activities of Phenylephrine.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Phenylephrine.Approved, Investigational
DobutamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Dobutamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Dopamine.Approved
DosulepinDosulepin may increase the vasopressor activities of Phenylephrine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
DoxepinDoxepin may increase the vasopressor activities of Phenylephrine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Phenylephrine.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Phenylephrine.Approved
EpanololThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Phenylephrine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Phenylephrine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Phenylephrine.Approved
EsmirtazapineEsmirtazapine may increase the vasopressor activities of Phenylephrine.Investigational
EtilefrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Fenozolone.Experimental
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Phenylephrine.Approved, Illicit, Investigational, Vet Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Phenylephrine.Approved, Investigational, Vet Approved
HarmalineHarmaline may increase the hypertensive activities of Phenylephrine.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Phenylephrine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Phenylephrine.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Hydroxyamphetamine.Approved
ImipramineImipramine may increase the vasopressor activities of Phenylephrine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Phenylephrine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenylephrine.Approved, Investigational
Ioflupane I-123Phenylephrine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the vasopressor activities of Phenylephrine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Phenylephrine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Phenylephrine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Phenylephrine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Isoprenaline.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Isoxsuprine.Approved, Withdrawn
LabetalolLabetalol may decrease the vasoconstricting activities of Phenylephrine.Approved
LacidipinePhenylephrine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Phenylephrine.Approved, Investigational
LinezolidLinezolid may increase the hypertensive activities of Phenylephrine.Approved, Investigational
LisurideLisuride may increase the hypertensive activities of Phenylephrine.Approved, Investigational
LofepramineLofepramine may increase the vasopressor activities of Phenylephrine.Experimental
LorpiprazoleThe therapeutic efficacy of Phenylephrine can be increased when used in combination with Lorpiprazole.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive activities of Phenylephrine.Illicit, Investigational, Withdrawn
MebanazineMebanazine may increase the hypertensive activities of Phenylephrine.Withdrawn
MefenorexThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Metaraminol.Approved, Investigational
MetergolineMetergoline may increase the hypertensive activities of Phenylephrine.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Methoxamine.Approved, Investigational
Methylene blueMethylene blue may increase the hypertensive activities of Phenylephrine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Phenylephrine.Approved
MethysergideMethysergide may increase the hypertensive activities of Phenylephrine.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Phenylephrine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Phenylephrine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Phenylephrine.Approved
MirtazapineMirtazapine may increase the vasopressor activities of Phenylephrine.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Phenylephrine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Phenylephrine.Approved, Investigational
NialamideNialamide may increase the hypertensive activities of Phenylephrine.Withdrawn
NicergolineNicergoline may increase the hypertensive activities of Phenylephrine.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Phenylephrine.Approved
NortriptylineNortriptyline may increase the vasopressor activities of Phenylephrine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Phenylephrine.Withdrawn
OpipramolOpipramol may increase the vasopressor activities of Phenylephrine.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Orciprenaline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Oxymetazoline.Approved, Investigational
PargylinePargyline may increase the hypertensive activities of Phenylephrine.Approved
Patent BlueThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Patent Blue.Approved
PergolidePergolide may increase the hypertensive activities of Phenylephrine.Approved, Investigational, Vet Approved, Withdrawn
PhenelzinePhenelzine may increase the hypertensive activities of Phenylephrine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Phenylephrine.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Phenmetrazine.Approved, Illicit
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Phenylephrine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phenylephrine.Approved, Illicit
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Phenylephrine.Approved, Vet Approved, Withdrawn
PirlindolePirlindole may increase the hypertensive activities of Phenylephrine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Phenylephrine.Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Prenalterol.Experimental
ProcarbazineProcarbazine may increase the hypertensive activities of Phenylephrine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Procaterol.Approved, Investigational
PropacetamolThe serum concentration of Phenylephrine can be increased when it is combined with Propacetamol.Approved, Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Phenylephrine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Pseudoephedrine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Racepinephrine.Approved
RasagilineRasagiline may increase the hypertensive activities of Phenylephrine.Approved
RitodrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Ritodrine.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Phenylephrine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Phenylephrine.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Phenylephrine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Phenylephrine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Phenylephrine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Phenylephrine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline.Approved
TergurideTerguride may increase the hypertensive activities of Phenylephrine.Experimental
TetryzolineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tetryzoline.Approved
TianeptineTianeptine may increase the vasopressor activities of Phenylephrine.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Phenylephrine.Approved
TramazolineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tramazoline.Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Phenylephrine.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tretoquinol.Experimental
TrimazosinTrimazosin may decrease the vasoconstricting activities of Phenylephrine.Experimental
TrimipramineTrimipramine may increase the vasopressor activities of Phenylephrine.Approved
TyramineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Phenylephrine.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Phenylephrine.Approved
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Franz Dietrich Klinger, Lienhard Wolter, Wolfgang Dietrich, "Method for preparing of L-phenylephrine hydrochloride." U.S. Patent US6187956, issued February, 1976.

US6187956
General References
Not Available
External Links
Human Metabolome Database
HMDB0002182
KEGG Compound
C07441
PubChem Compound
6041
PubChem Substance
46506961
ChemSpider
5818
ChEBI
8093
ChEMBL
CHEMBL1215
Therapeutic Targets Database
DAP000224
PharmGKB
PA450935
IUPHAR
485
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Phenylephrine
ATC Codes
R01AA04 — PhenylephrineS01FB01 — PhenylephrineR01BA53 — Phenylephrine, combinationsS01GA05 — PhenylephrineR01BA03 — PhenylephrineS01GA55 — Phenylephrine, combinationsC01CA06 — PhenylephrineR01AB01 — Phenylephrine
AHFS Codes
  • 12:12.04 — Alpha-adrenergic Agonists
  • 52:24.00 — Mydriatics
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents
  • 52:32.00 — Vasoconstrictors
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentCardiac Output,Low / Hemodynamics Instability / Obstetrical Complication of Anesthesia1
0RecruitingDiagnosticPostural Tachycardia Syndrome / Syncope, Vasovagal1
1CompletedBasic ScienceRhinitis1
1CompletedPreventionIntraocular Pressure1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentNasal Stuffiness1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingOtherHigh Blood Pressure (Hypertension) / Hypertension,Essential1
1RecruitingTreatmentBlood Loss,Surgical1
1TerminatedSupportive CareMucositis / Vesicular Stomatitis1
1Unknown StatusTreatmentArterial Hypotension / Arterial hypoxia1
1, 2CompletedSupportive CareOvarian Cysts1
1, 2CompletedTreatmentPain, Acute1
1, 2TerminatedSupportive CareNeoplasms / Oral Mucosa / Transplant-Related Disorder1
1, 2WithdrawnNot AvailableArrythmias / Blood Pressures / Heart Rate1
2CompletedPreventionAdverse Anesthesia Outcome1
2CompletedPreventionArterial Hypotension / Valve Surgery1
2CompletedPreventionObstetrical Anesthesia / Spinal Anaesthesia1
2CompletedPreventionOrthopedic Surgery of Lower Limb1
2CompletedTreatmentAcute Ischemic Stroke (AIS)1
2CompletedTreatmentAcute Lung Injury (ALI)1
2CompletedTreatmentBronchiolitis1
2CompletedTreatmentMydriasis1
2CompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
2CompletedTreatmentRhinitis / Seasonal Rhinitis1
2CompletedTreatmentShock, Septic2
2RecruitingPreventionStress Disorders, Post-Traumatic1
2, 3CompletedTreatmentArterial Hypotension1
2, 3RecruitingPreventionSpinal Hypotension1
2, 3SuspendedPreventionPost-operative Cognitive Dysfunction1
3CompletedTreatmentArterial Hypotension / Fluid Therapy1
3CompletedTreatmentCongenital Cataract / Unilateral Cataract Extraction1
3CompletedTreatmentEye Diseases1
3CompletedTreatmentNasal Congestion and Inflammations / Rhinitis1
3CompletedTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR) / Vasomotor Rhinitis1
3Not Yet RecruitingTreatmentCold1
3RecruitingTreatmentProgressing Stroke / Stroke, Acute1
3TerminatedTreatmentPremature Births / Retinal Anomalies1
3Unknown StatusTreatmentAcute Rhinitis / Flu-like Syndromes1
3WithdrawnTreatmentIncontinence, Fecal1
3WithdrawnTreatmentAcute Rhinitis1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4CompletedNot AvailableAcute Rhinitis / Flu caused by Influenza1
4CompletedBasic ScienceEndotoxaemia1
4CompletedDiagnosticPreterm Infants1
4CompletedPreventionAdverse Effects / Anesthesia, Spinal and Epidural / Arterial Hypotension / Complications, Cesarean Section1
4CompletedPreventionAnesthetic Complication Spinal1
4CompletedPreventionArterial Hypotension1
4CompletedPreventionEffects of; Anesthesia, in Labor and Delivery1
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionHypotension Drug-Induced1
4CompletedTreatmentAnaesthesia / Arterial Hypotension1
4CompletedTreatmentArterial Hypotension2
4CompletedTreatmentArterial Hypotension / Cardiac Output / Cesarean Section1
4CompletedTreatmentComplications; Cesarean Section1
4CompletedTreatmentCough Reflex Sensitivity1
4CompletedTreatmentPregnancy1
4CompletedTreatmentShock, Septic1
4Enrolling by InvitationOtherCataracts1
4RecruitingPreventionCesarean Section Complications / Spinal Anaesthesia4
4RecruitingPreventionSpinal Anesthetics Causing Adverse Effects in Therapeutic Use1
4RecruitingTreatmentArterial Hypotension2
4RecruitingTreatmentBrain Microcirculation and Oxygenation / Neoplasms, Brain1
4RecruitingTreatmentCardiac Output Change Following Ephedrine, Phenylephrine, Norepinephrine, Ondansetron / Cardiac Output, Low1
4RecruitingTreatmentOxygenation During One Lung Ventilation1
4RecruitingTreatmentShock1
4RecruitingTreatmentProphylaxis of preeclampsia1
4TerminatedPreventionSpinal Induced Hypotension in Cesarean Delivery1
4TerminatedTreatmentCritical Illness1
4TerminatedTreatmentPregnancy / Spinal Anaesthesia1
4Unknown StatusNot AvailableEndovascular Carotid Surgery / Preoperative Hypotension1
4Unknown StatusDiagnosticRefractive Errors1
4Unknown StatusTreatmentArrythmias / Sepsis / Shock / Shock, Septic / Tachycardia1
4Unknown StatusTreatmentVitiligo1
Not AvailableActive Not RecruitingBasic ScienceAssess Phenylephrine on EVP and IOP1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableLeiomyomas1
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceHypovolaemia / Temperature Change, Body1
Not AvailableCompletedBasic ScienceInsulin Sensitivity / Microcirculation1
Not AvailableCompletedOtherBioequivalence / Healthy Volunteers1
Not AvailableCompletedOtherVascular Reaction to Medications1
Not AvailableCompletedPreventionAnaesthesia therapy / Disorder of Shoulder1
Not AvailableCompletedPreventionArterial Hypotension / Nausea1
Not AvailableCompletedPreventionCesarean Delivery1
Not AvailableCompletedPreventionHypotension After Reperfusion in Liver Transplantation1
Not AvailableCompletedScreeningRetinopathy of Prematurity (ROP)1
Not AvailableCompletedSupportive CareComplex Regional Pain Syndrome (CRPS)1
Not AvailableCompletedTreatmentArterial Hypotension1
Not AvailableCompletedTreatmentArterial Hypotension / Preeclampsia1
Not AvailableCompletedTreatmentArterial Hypotension / Shock1
Not AvailableCompletedTreatmentBlood Pressures / Nasal Bleeding1
Not AvailableCompletedTreatmentBloodpressure1
Not AvailableCompletedTreatmentCaesarean Sections1
Not AvailableCompletedTreatmentHeart Failure, Unspecified1
Not AvailableRecruitingNot AvailablePostural Tachycardia Syndrome1
Not AvailableRecruitingOtherAutonomic Nervous System Diseases / Cardiac Dysrhythmia / Cardiovascular Disease (CVD) / Orthostatic Intolerance / Postural Orthostatic Tachycardia Syndrome (POTS) / Postural Tachycardia Syndrome / Primary Dysautonomias / Tachycardia1
Not AvailableRecruitingOtherCataracts1
Not AvailableRecruitingPreventionArterial Hypotension2
Not AvailableRecruitingPreventionArterial Hypotension / Complications; Cesarean Section1
Not AvailableRecruitingTreatmentAging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium1
Not AvailableTerminatedBasic ScienceHealthy Volunteers2
Not AvailableTerminatedBasic ScienceProphylaxis of cardiomyopathy / Stress-induced (Takotsubo) Cardiomyopathy1
Not AvailableUnknown StatusDiagnosticPreeclampsia1
Not AvailableUnknown StatusTreatmentCarotid Stenosis / Intra-operative Hypotension1
Not AvailableUnknown StatusTreatmentArterial hypoxia1
Not AvailableWithdrawnTreatmentComplications; Cesarean Section / Spinal Anesthetics Causing Adverse Effects in Therapeutic Use1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Accutome Inc.
  • Advanced Pharmaceutical Services Inc.
  • Advent Pharmaceuticals Inc.
  • Aero Pharmaceuticals Inc.
  • AG Marin Pharmaceuticals
  • Akorn Inc.
  • Alba Pharmacal
  • Alcon Laboratories
  • Allegis Pharmaceuticals
  • Allergy Laboratories Inc.
  • Altaire Pharmaceuticals
  • Ambi Pharmaceuticals Inc.
  • Amend
  • American Regent
  • Amneal Pharmaceuticals
  • Anip Acquisition Co.
  • A-S Medication Solutions LLC
  • Athlon Pharmaceuticals Inc.
  • Auriga Pharmaceuticals LLC
  • Baroli
  • Bausch & Lomb Inc.
  • Baxter International Inc.
  • Bayer Healthcare
  • Bio Pharm Inc.
  • Blansett Pharmacal Co. Inc.
  • Boca Pharmacal
  • Breckenridge Pharmaceuticals
  • Brookstone Pharmaceuticals
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • Burel Pharmaceuticals Inc.
  • Capellon Pharmaceuticals LLC
  • Cardinal Health
  • Centurion Labs
  • Chain Drug
  • Chemins Co. Inc.
  • Claris Lifesciences Inc.
  • Conta Care Ophthalmics and Diagnostics
  • Contract Pharm
  • Cornerstone Pharmacy
  • Cypress Pharmaceutical Inc.
  • Deca Pharmaceuticals LLC
  • Deltex Pharmaceuticals Inc.
  • Deston Therapeutics
  • Dexo LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DSC Laboratories
  • Ebewe Pharma
  • Econolab Inc.
  • Edwards Pharmaceuticals
  • Emerson Labs
  • Endo Pharmaceuticals Inc.
  • Everett Laboratories Inc.
  • Eye Care and Cure Corp.
  • Eye Supply Usa Inc.
  • Falcon Pharmaceuticals Ltd.
  • Gayheart Pharmaceutical Inc.
  • Gentex Pharma LLC
  • Gil Pharmaceutical Corp.
  • Gm Pharmaceuticals Inc.
  • Great Southern Laboratories
  • Hawthorn Pharmaceuticals
  • Hi Tech Pharmacal Co. Inc.
  • Hospira Inc.
  • HUB Pharmaceuticals
  • International Ethical Labs Inc.
  • Invision Pharmaceuticals
  • Iopharm Laboratories Inc.
  • Irisys Inc.
  • Jaymac Pharmaceuticals LLC
  • Kowa Pharmaceuticals America Inc.
  • Kylemore Pharmaceuticals
  • Lark Pharmaceuticals Inc.
  • Larken Laboratories Inc.
  • Laser Pharmaceuticals
  • Luitpold Pharmaceuticals Inc.
  • Lunsco Inc.
  • Macoven Pharmaceuticals LLC
  • Major Pharmaceuticals
  • Marnel Pharmaceuticals Inc.
  • MCR American Pharmaceuticals Inc.
  • Med Tek Pharmaceuticals Inc.
  • Meda AB
  • Medique Products
  • Midland Healthcare LLC
  • Midland Pharmaceutical LLC
  • Midlothian Labs
  • Monte Sano Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nadin Co.
  • Neilgen Pharma Inc.
  • Nephron Pharmaceuticals Corp.
  • Nexgen Pharma Inc.
  • Nolco Pharmaceuticals Inc.
  • Norega Laboratories Inc.
  • Novis PR Inc.
  • Nucare Pharmaceuticals Inc.
  • Numark Laboratories Inc.
  • Ocusoft
  • Optopics
  • Palm Pharmaceuticals LLC
  • Palmetto Pharmaceuticals Inc.
  • Pamlab LLC
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pharmaceutical Generic Developers Inc.
  • Pharmedium
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Portal Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Quality Home Products
  • Quality Research Pharmaceutical Inc.
  • Rebel Distributors Corp.
  • Respa Pharmaceuticals Inc.
  • Rico Pharmacal
  • River's Edge Pharmaceuticals
  • Rugby Laboratories
  • Rx Formulations Corp.
  • Sanofi-Aventis Inc.
  • Scherer Labs
  • Schwarz Pharma Inc.
  • Scientific Laboratories Inc.
  • Seatrace Pharmaceuticals Inc.
  • Seyer Pharmatec Inc.
  • Silarx Pharmaceuticals
  • Sonar Products Inc.
  • Sorter Labs
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • Stesso Pharmaceuticals LLC
  • Summa Rx Laboratories Inc.
  • Teral Laboratories
  • Teva Pharmaceutical Industries Ltd.
  • TG United Inc.
  • Tiber Pharmaceuticals LLC
  • Tri Med Laboratories Inc.
  • Trigen Laboratories Inc.
  • United Research Laboratories Inc.
  • US Pharmaceutical Corp.
  • Varsity Laboratories
  • Vertical Pharmaceuticals Inc.
  • Vetco Pharma
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • Walgreen Co.
  • Wilson Ophthalmic Corp.
  • Wockhardt Ltd.
  • WraSer Pharmaceuticals
  • Zyber Pharmaceuticals
Dosage forms
FormRouteStrength
Capsule, liquid filledOral
Granule, effervescentOral
Tablet, effervescentOral
StripOral10 mg
SolutionOral1.25 mg
Solution / dropsOral
Suspension / dropsOral
LiquidTopical
Tablet, chewableOral
LiquidOral
SolutionOral2.5 mg/5mL
Kit
Tablet, coatedOral
TabletOral5 mg/1
KitOral
GelRectal
Kit
PowderOral
CapsuleOral
TabletOral5 1/1
LiquidOral2.5 mg/5mL
ElixirOral
Tablet, extended releaseOral
SprayNasal21.73 mg/15mL
SprayNasal10 mg/mL
SolutionNasal1.25 mg/mL
OintmentRectal; Topical
ClothTopical
Kit; tabletOral
Solution / dropsNasal
CreamRectal; Topical
SuspensionOral
TabletOral10 mg/1
SolutionOral
CreamTopical
Tablet, film coatedOral
Tablet, film coatedOral5 mg/1
OintmentRectal
OintmentTopical
SuppositoryRectal
GelTopical
OintmentTopical0.25 %
SprayTopical
Kit; powderOral
Kit; powder, for solutionOral
Tablet, orally disintegratingOral
CreamRectal
LiquidNasal0.125 %
LiquidNasal1.25 mg/mL
LiquidNasal.00125 mg/mL
Solution / dropsOphthalmic10 %
Solution / dropsOphthalmic2.5 %
LiquidOphthalmic2.5 %
Tablet, coatedOral10 mg/1
Solution / dropsTopical.25 g/100mL
SprayTopical.25 g/100mL
Solution / dropsNasal1 %
SolutionIntramuscular; Intravenous; Subcutaneous1 %
SprayNasal1 g/100mL
SprayNasal.25 g/100mL
SprayNasal.5 g/100mL
LiquidIntramuscular; Intravenous; Subcutaneous1 %
StripOral
Tablet, multilayerOral
Solution / dropsNasal1 g/100mL
LiquidOral5 mg
LotionOphthalmic
SolutionOphthalmic2.5 %
SolutionOphthalmic
Injection, solution, concentrateIntraocular
Injection, solutionIntravenous.08 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous100 ug/mL
Injection, solutionIntravenous160 ug/mL
Injection, solutionIntravenous300 ug/mL
Injection, solutionIntravenous40 ug/mL
Injection, solutionIntravenous50 ug/mL
InjectionIntramuscular; Intravenous; Subcutaneous10 mg/mL
InjectionIntravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous10 mg/mL
SolutionOphthalmic25 mg/mL
Solution / dropsOphthalmic2.5 mg/mL
SolutionIntravenous50 mcg
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
Solution / dropsOphthalmic100 mg/mL
Solution / dropsOphthalmic25 mg/mL
Tablet, film coatedOral10 mg/1
LiquidOphthalmic.12 %
GelRectal; Topical
Capsule, gelatin coatedOral
SuppositoryRectal0.25 %
Capsule, coatedOral
SprayNasal
TabletOral10 mg
TabletOral5 mg
Powder, for solutionOral
SyrupOral
LiquidNasal1 mL/100mL
StripOral2.5 mg
Solution / dropsOphthalmic
Powder, for suspensionOral
TabletOral
Granule, for solutionOral
LiquidOphthalmic
Prices
Unit descriptionCostUnit
Mydfrin 2.5% Solution 5ml Bottle37.1USD bottle
Neo-synephrine 10 mg/ml amp5.68USD ml
Mydfrin 2.5% eye drops5.28USD ml
Phenylephrine 10 mg/ml vial3.0USD ml
Phenylephrine 2.5% eye drop2.09USD ml
Neofrin 10% eye drops1.93USD ml
Ak-dilate 10% eye drops1.34USD ml
Phenylephrine hcl crystals1.34USD g
Phenylephrine 10% eye drops1.25USD ml
Phenylephrine-ns 0.8 mg/10 ml1.2USD ml
Phenylephrine-ns 0.4 mg/10 ml1.17USD ml
Mydfrin 2.5 % Solution1.09USD ml
Neofrin 2.5% eye drops0.6USD ml
Ak-dilate 2.5% eye drops0.45USD ml
Neo-synephrine 0.25% drops0.36USD ml
Hemorrhoidal suppository0.28USD suppository
Neo-synephrine 12 hour spray0.28USD ml
Neo-synephrine 1% drops0.26USD ml
Sudafed pe 10 mg tablet0.25USD tablet
Neo-synephrine 0.5% drops0.23USD ml
Little noses decon nose drp0.22USD ml
Wal-phed pe 10 mg tablet0.22USD tablet
Tur-bi-kal nose drops0.21USD ml
Industrial 0.12% eye drops0.17USD ml
Ephrine 1% nose drops0.15USD ml
Phenylephrine 10 mg tablet0.08USD tablet
Rhinall 0.25% nose drops0.07USD ml
Non-pseudo sinus decongest tablet0.05USD tablet
Pv nasal decongestant 5 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8173707Yes2004-01-302024-01-30Us
US9278101Yes2004-01-302024-01-30Us
US8586633Yes2004-01-302024-01-30Us
US9066856Yes2014-04-232034-04-23Us
US8859623No2013-11-142033-11-14Us
US9399040Yes2004-01-302024-01-30Us
US9486406Yes2014-04-232034-04-23Us
US9855246No2013-10-232033-10-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)140-145 °CNot Available
water solubilityFreely soluble in waterNot Available
logP-0.31HANSCH,C ET AL. (1995)
pKa8.97SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility22.0 mg/mLALOGPS
logP-0.69ALOGPS
logP-0.07ChemAxon
logS-0.88ALOGPS
pKa (Strongest Acidic)9.07ChemAxon
pKa (Strongest Basic)9.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity47.25 m3·mol-1ChemAxon
Polarizability18.2 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier-0.9115
Caco-2 permeable-0.7294
P-glycoprotein substrateSubstrate0.5308
P-glycoprotein inhibitor INon-inhibitor0.9527
P-glycoprotein inhibitor IINon-inhibitor0.9109
Renal organic cation transporterNon-inhibitor0.856
CYP450 2C9 substrateNon-substrate0.7882
CYP450 2D6 substrateNon-substrate0.7756
CYP450 3A4 substrateNon-substrate0.6946
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9646
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9088
CYP450 3A4 inhibitorNon-inhibitor0.858
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9594
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8841
BiodegradationReady biodegradable0.7647
Rat acute toxicity2.6480 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5164
hERG inhibition (predictor II)Non-inhibitor0.8717
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.12 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-014i-0900000000-b11a2a880d1683fa6cae
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-01b9-6900000000-bbdd210a846be116dbcd
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0900000000-b11a2a880d1683fa6cae
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-01b9-6900000000-bbdd210a846be116dbcd
MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)LC-MS/MSsplash10-0udi-0900000000-d95a741ffcfe3f7bb7e9
MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)LC-MS/MSsplash10-0006-9800000000-7695881b36499169fb71
MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)LC-MS/MSsplash10-054o-9200000000-888fce606d860cd39be2
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-014i-0900000000-edfcbc18ccdb6872b791
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-00di-0900000000-15132688bbc7ac0be42f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-00di-2900000000-34ccc7192518d4c14210
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-00di-3900000000-e619f4210f81c11f61be
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-00dl-6900000000-3178337a019ac9bf313d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-0gb9-0900000000-e738818606836c1d6d1a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-0udi-0900000000-36b72327f64f1355a502
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-052o-4900000000-935a9659fe39602b138d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-052f-9800000000-7d83555b537d6fec673b
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-054o-9400000000-5ef2f6d1da57087e6ac7
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-014i-0900000000-4a910a2109ba191b96e7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-edfcbc18ccdb6872b791
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0900000000-15132688bbc7ac0be42f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-2900000000-34ccc7192518d4c14210
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-3900000000-e8a5a4f1aae0796866a7
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00dl-6900000000-3178337a019ac9bf313d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-c0d824f22be752d523b4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-4fb67ae2344d097c3abb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-113e95fddc78edd9df82
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0zg3-2900000000-a52b0d450061f2762c71
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052o-4900000000-1919f188c550710ea860
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-6900000000-93a02b958e60eadd5bfb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0gb9-0900000000-e738818606836c1d6d1a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0900000000-36b72327f64f1355a502
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052o-4900000000-5c34ff7c978e4b607f00
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052f-9800000000-036a3eb2e3b11f203fd4
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-054o-9400000000-284961abd6764baa0d1d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-4a910a2109ba191b96e7
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
1-hydroxy-4-unsubstituted benzenoids
Direct Parent
1-hydroxy-4-unsubstituted benzenoids
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Alcohol / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenylethanolamines, secondary amino compound (CHEBI:8093)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Martinez-Salas SG, Campos-Peralta JM, Pares-Hipolito J, Gallardo-Ortiz IA, Ibarra M, Villalobos-Molina R: Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol. 2007 Jul;27(3):137-42. [PubMed:17584443]
  2. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6. [PubMed:17658513]
  3. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, Wieland DM: Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996 Dec;37(12):1923-31. [PubMed:8970507]
  2. Raffel DM, Corbett JR, del Rosario RB, Mukhopadhyay SK, Gildersleeve DL, Rose P, Wieland DM: Sensitivity of [11C]phenylephrine kinetics to monoamine oxidase activity in normal human heart. J Nucl Med. 1999 Feb;40(2):232-8. [PubMed:10025828]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:59